WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 206128
Description: Entasobulin is a β-tubulin polymerization inhibitor with potential anticancer activity. Entasobulin is a indolizine-glyoxylamide based small molecule that demonstrate substantial in vitro anti-proliferative activities against cancer cell lines, including multidrug resistance (MDR) phenotypes. The in vitro cytotoxic effects have been demonstrated across a wide array of tumor types of various origins (e.g., breast, colon, uterine).
MedKoo Cat#: 206128
Chemical Formula: C26H18ClN3O2
Exact Mass: 439.10875
Molecular Weight: 439.89
Elemental Analysis: C, 70.99; H, 4.12; Cl, 8.06; N, 9.55; O, 7.27
Entasobulin is not in stock, but is available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to firstname.lastname@example.org to inquire quote.
Synonym: Entasobulin; UNIITB77GU6BFO. Pubchem SID 175427608.
IUPAC/Chemical Name: 2-(1-(4-chlorobenzyl)-1H-indol-3-yl)-2-oxo-N-(quinolin-6-yl)acetamide.
InChi Key: LJIUXAHLYIPHOK-UHFFFAOYSA-N
InChi Code: InChI=1S/C26H18ClN3O2/c27-19-9-7-17(8-10-19)15-30-16-22(21-5-1-2-6-24(21)30)25(31)26(32)29-20-11-12-23-18(14-20)4-3-13-28-23/h1-14,16H,15H2,(H,29,32)
SMILES Code: O=C(NC1=CC=C2N=CC=CC2=C1)C(C3=CN(CC4=CC=C(Cl)C=C4)C5=C3C=CC=C5)=O
The following data is based on the product molecular weight 439.89 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: James DA, Koya K, Li H, Liang G, Xia Z, Ying W, Wu Y, Sun L. Indole- and indolizine-glyoxylamides displaying cytotoxicity against multidrug resistant cancer cell lines. Bioorg Med Chem Lett. 2008 Mar 15;18(6):1784-7. doi: 10.1016/j.bmcl.2008.02.029. Epub 2008 Feb 16. PubMed PMID: 18308566.